Canaccord Genuity Maintains a 'Buy' on Optimer Pharmaceuticals (OPTR); DIFICID Uptake Appears Steady
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $20.00.
Canaccord analyst, George Farmer, said, "Positive script trends over the first three months since DIFICID launch for treatment of C. diff. infection (CDI) support our view of its strong potential...In our view, DIFICID approval as a new CDI treatment option and steady formulary adoption should enable grab of Vancocin share. However, comparison of DIFICID vs. Vancocin script trend shows relatively flat Vancocin script numbers since Dificid launch, per WK (Figure 2). This may reflect the majority of DIFICID application post-Vancocin use. Upside could come from increased first-line uptake as doctors gain more clinical experience with the drug."
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $13.21 yesterday.
Canaccord analyst, George Farmer, said, "Positive script trends over the first three months since DIFICID launch for treatment of C. diff. infection (CDI) support our view of its strong potential...In our view, DIFICID approval as a new CDI treatment option and steady formulary adoption should enable grab of Vancocin share. However, comparison of DIFICID vs. Vancocin script trend shows relatively flat Vancocin script numbers since Dificid launch, per WK (Figure 2). This may reflect the majority of DIFICID application post-Vancocin use. Upside could come from increased first-line uptake as doctors gain more clinical experience with the drug."
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $13.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
